908 Devices (NASDAQ:MASS) Director Christopher Brown Sells 9,442 Shares

908 Devices Inc. (NASDAQ:MASS) Director Christopher Brown sold 9,442 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $9.03, for a total transaction of $85,261.26. Following the transaction, the director directly owned 813,917 shares in the company, valued at approximately $7,349,670.51. This represents a 1.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

908 Devices Stock Performance

NASDAQ:MASS traded up $0.01 during trading hours on Wednesday, reaching $10.02. The company’s stock had a trading volume of 858,415 shares, compared to its average volume of 312,253. The firm has a market capitalization of $378.90 million, a price-to-earnings ratio of -10.02 and a beta of 0.66. The firm has a 50-day simple moving average of $8.23 and a 200-day simple moving average of $7.34. 908 Devices Inc. has a 1 year low of $5.03 and a 1 year high of $10.52.

908 Devices (NASDAQ:MASS) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. 908 Devices had a negative net margin of 62.40% and a negative return on equity of 14.03%. The business had revenue of $16.07 million during the quarter, compared to analyst estimates of $15.37 million. Equities analysts anticipate that 908 Devices Inc. will post -0.4 earnings per share for the current fiscal year.

908 Devices News Roundup

Here are the key news stories impacting 908 Devices this week:

• Positive Sentiment: Q2 results exceeded expectations. 908 Devices reported revenue of $16.07 million, up 23% year over year and above the $15.37 million analyst estimate. Its adjusted loss of $0.11 per share was narrower than the expected $0.14 loss and improved from a $0.18 loss a year earlier. 908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects 2026 revenue of $68 million to $70 million, lifting the low end of its prior outlook and broadly bracketing the $68.6 million consensus estimate. The outlook excludes potential AVCAD revenue, leaving possible upside if that business contributes. 908 Devices signals 68M-70M 2026 revenue outlook
• Positive Sentiment: Demand and recurring revenue remain key growth drivers. Law-enforcement, defense, and other mission-critical customers are supporting demand for chemical detection devices. Recurring revenue from NIRLab and upgrades such as VipIR may provide additional stability, while management said the adjusted EBITDA loss narrowed by more than half year over year. 908 Devices: Mission Critical Devices Drive Growth
• Neutral Sentiment: 908 Devices plans to present at the 17th Annual Midwest IDEAS Investor Conference, providing an opportunity for management to discuss its outlook and growth strategy. 908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
• Neutral Sentiment: Reported short interest was listed at zero shares, offering no meaningful evidence of short-selling pressure or potential short-covering demand.
• Negative Sentiment: The company remains unprofitable, with a negative net margin and return on equity. Although losses improved, continued negative EPS and the stock’s sharp recent appreciation could increase valuation sensitivity if growth or guidance disappoints.

Institutional Trading of 908 Devices

A number of institutional investors have recently modified their holdings of the company. First Light Asset Management LLC grew its stake in shares of 908 Devices by 25.6% in the first quarter. First Light Asset Management LLC now owns 6,072,563 shares of the company’s stock worth $37,164,000 after purchasing an additional 1,236,377 shares during the last quarter. ARK Investment Management LLC lifted its holdings in 908 Devices by 1.6% in the 4th quarter. ARK Investment Management LLC now owns 1,985,986 shares of the company’s stock worth $10,426,000 after buying an additional 32,214 shares during the period. BlackRock Inc. purchased a new stake in 908 Devices in the 2nd quarter worth approximately $16,915,000. Needham Investment Management LLC grew its position in shares of 908 Devices by 246.8% in the 4th quarter. Needham Investment Management LLC now owns 770,000 shares of the company’s stock worth $4,042,000 after buying an additional 548,000 shares during the last quarter. Finally, Granahan Investment Management LLC grew its position in shares of 908 Devices by 662.6% in the 1st quarter. Granahan Investment Management LLC now owns 695,070 shares of the company’s stock worth $4,254,000 after buying an additional 603,929 shares during the last quarter. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on MASS shares. Weiss Ratings restated a “sell (d-)” rating on shares of 908 Devices in a research report on Friday. Roth Capital increased their price objective on 908 Devices from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen cut shares of 908 Devices from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. Finally, Stifel Nicolaus lifted their target price on shares of 908 Devices from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $12.50.

908 Devices Company Profile

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.